Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 1609
New York,
NY 10170
United States - Map
Phone: 212-297-0020
Fax: 212-297-0019
Website: http://www.synergypharma.com
| Index Membership: | N/A | | Sector: | Healthcare | | Industry: | Drug Manufacturers - Other | | Full Time Employees: | 18 |
|
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has completed Phase IIa clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase I clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. Key Statistics
| |
| | Pay | Exercised | Dr. Gary S. Jacob Ph.D.,
66
Chief Exec. Officer, Pres and Director | 562.00k | 0.00 | Mr. Bernard F. Denoyer CPA, M.B.A.,
65
Principal Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec. | 246.00k | 0.00 | Dr. Kunwar Shailubhai Ph.D.,
55
Chief Scientific Officer | 317.00k | 0.00 | Dr. Laura Barrow Pharm. D.,
Sr. VP of Clinical Operations | N/A | N/A | Dr. Stephen Comiskey Ph.D.,
VP of Product Devel. | N/A | N/A |
|
| | Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.08%